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Local lentiviral short hairpin RNA silencing
of CCR2 inhibits vein graft thickening in
hypercholesterolemic apolipoprotein
E3-Leiden mice
Daniël Eefting, MD,a,b Ilze Bot, PhD,c Margreet R. de Vries, BSc,b Abbey Schepers, MD, PhD,a,b
J. Hajo van Bockel, MD, PhD,b Theo J. C. Van Berkel, PhD,c Erik A. L. Biessen, PhD,c,d and
Paul H. A. Quax, PhD,b Leiden and Maastricht, The Netherlands
Objective: Inflammatory responses to vascular injury are key events in vein graft disease and accelerated atherosclerosis,
which may result in bypass failure. The monocyte chemoattractant protein-1 (MCP-1)/CC-chemokine receptor (CCR)-2
pathway is hypothesized to play a central role. A murine model for vein graft disease was used to study the effect of local
application of lentiviral short hairpin RNA (shRNA) targeted against CCR2.
Methods: A venous interposition was placed into the carotid artery of hypercholesterolemic apolipoprotein E3-Leiden
(APOE*3-Leiden) mice to induce vein graft thickening with features of accelerated atherosclerosis. To demonstrate the
efficacy of the lentiviral shRNA targeting murine CCR2 (shCCR2) in blocking vein graft disease in vivo, lentiviral
shCCR2 or a control lentivirus was used to infect the vein graft locally (n  8).
Results: Vascular CCR2 and MCP-1 messenger RNA expression levels were significantly upregulated during lesion
progression in the vein graft. Infection of smooth muscle cells (SMCs) with a lentiviral shRNA targeting shCCR2
completely abolished MCP-1–induced SMC migration and inhibited SMC proliferation in vitro (n  3 per group).
Morphometric analysis of sections of grafts showed a significant 38% reduction in vein graft thickening in the
shCCR2-treated mice 4 weeks after surgery (control, 0.42  0.05 mm2; shCCR2, 0.26  0.03 mm2; P  .007).
Conclusion: Vascular CCR2 contributes to vein graft disease, and local application of shRNA against CCR2 to the vessel
wall prevents vein graft thickening in hypercholesterolemic mice, suggesting that local overexpressing of shRNA using
organ-targeted lentiviral gene delivery may be a promising therapeutic tool to improve vein graft disease in bypassed
patients. ( J Vasc Surg 2009;50:152-60.)
Clinical Relevance: Vein graft disease is an important clinical issue that results from an inflammatory response. The
monocyte chemoattractant protein (MCP)-1/CC-chemokine receptor (CCR)-2 pathway plays a key role in the initiation
and development of vein graft disease. This study demonstrates that perivascular overexpression of short hairpin RNA,
targeted against CCR2, inhibits vein graft thickening. These data show that organ-targeted gene therapy against CCR2
in the vessel wall could be a promising therapeutic tool to improve vein graft patency in bypassed patients.From Gaubius Laboratory, TNO Quality of Life,a the Department of
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152Venous bypass graft surgery is a generally applied treatment
for peripheral and cardiac arterial occlusive disease. Failure of
the graft is a serious clinical problem, with a primary patency
after bypass surgery of 61% after 1 year, as reported in the
Project of Ex-vivo Vein Graft Engineering via Transfection
(PREVENT) III trial,1 up to 40% after 10 years, frequently
resulting inmyocardial infarction and the need for reinterven-
tions or limb amputations.2 The development of vein graft
thickening, mainly caused by intimal hyperplasia and acceler-
ated atherosclerosis, is triggered by inflammatory activation of
vascular cells and is the major cause of late graft failure.3
Vein graft thickening starts with the adhesion and influx
of monocytes into the intima of the vein graft. In addition,
vascular smooth muscle cells (SMCs) migrate and proliferate,
and macrophages accumulate in the vessel wall.4 Macro-
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foam cells, especially in a hypercholesterolemic environment,
which leads to accelerated atherosclerosis in the vein graft.5
Inflammation is thought to play a pivotal role in this
process.6 Key mediators in vascular inflammation are
monocyte chemoattractant protein-1 (MCP-1), one of the
most potent chemotactic agents to monocytes, and its
receptor CC-chemokine receptor 2 (CCR2).7 We recently
demonstrated that vein graft thickening in a mouse in vivo
model could be strongly inhibited by systemic overexpres-
sion of 7ND-MCP-1, a mutant form of MCP-1 that acts as
a dominant antagonist of CCR2.8
Because MCP-1 is a key chemokine in inflammatory
processes, prolonged systemic inhibition of MCP-1 may have
negative side effects. Thus, systemic overexpression of inhibi-
tors of the MCP-1/CCR2 pathway is not a preferred thera-
peutic treatment. We therefore designed the present study to
interfere in the MCP-1/CCR2 pathway locally in vein grafts
to prevent or reduce vein graft thickening by using a lentiviral
vector expressing a short hairpin RNA (shRNA) construct
developed againstCCR2 (shCCR2). This vectorwas found to
lead to effective silencing of CCR2 in vitro in CCR2-trans-
fected cells and also in vivo in a model of peritonitis.9 This
article describes the effect of shCCR2 on MCP-1–induced
SMC migration and SMC proliferation.
To assess the effect of shCCR2 in vivo, the study used a
venous interpositionmodel in apolipoprotein E3 (APOE*3)-
Leiden mice being fed a hypercholesterolemic diet. After a ve-
nous interposition is placed in the carotid artery of these mice,
vein graft disease consistingof vesselwall thickeningwith signs of
accelerated atherosclerosis develops4 weeks.10,11
We first studied CCR2 and MCP-1 messenger RNA
(mRNA) expression patterns in time in this vein graft
model, and finally, we describe the effect of locally applied
lentiviral shRNA against CCR2 on vein graft thickening in
the hypercholesterolemic APOE*3-Leiden mice.
METHODS
Mice and vein graft model. Animal experiments were
approved by the animal welfare committee of the Nether-
lands Organization for Applied Scientific Research (TNO,
Leiden, The Netherlands). For all experiments, 12-week-
old male APOE*3-Leiden mice on a C57BL/6 back-
ground, bred at the TNO Laboratory, were used. These
mice develop diet-dependent hypercholesterolemia (levels
between 7.5 and 12.5 mmol/L) and atherosclerosis.12 All
mice received water and food ad libitum. Animals were fed
with a cholesterol-enriched high-fat diet containing 1%
cholesterol and 0.05% cholate (Arie Blok B.V. The Neth-
erlands) starting 4 weeks before surgery and continuing
during the experiment.11 Cholesterol levels in serum were
determined 1 day before surgery and at euthanasia, using a
cholesterol esterase, cholesterol oxidase reaction (Chol R1;
Roche Diagnostics, The Netherlands). Before surgery and
euthanasia, mice were anesthetized by an intraperitoneal
injection with a combination of midazolam (5 mg/kg,
Roche, The Netherlands), medetomidine (0.5 mg/kg,
Orion, Finland), and fentanyl (0.05 mg/kg, Janssen-Cilag,The Netherlands). Mice with a mean weight of 26.7 
0.5 g were allocated randomly to the different experimental
groups (n  8 per group for the shCCR2 experiment and
n  3 per time point for the immunohistochemistry and
cytokine expression time courses).
For the vein graft model, a venous interposition was
placed in the carotid artery as described previously.10 Pho-
tographs of this vein graft model are available in the Appen-
dix Figure (online only). In brief, caval veins of donor mice
serving as vein grafts were harvested and preserved in 0.9%
saline containing 100 IU heparin. In the recipient mice, the
right carotid artery was dissected free from its surroundings
and cut midway. A polyethylene cuff was placed at the end
on both sides. The artery was everted around the cuff and
ligated at both ends. The caval vein was grafted by sleeving
the ends of the vein over two everted ends of the carotid
artery and ligating them together.
Vein graft thickening quantification and immuno-
histochemistry. At euthanasia, tissue segments were har-
vested after in vivo perfusion fixation with phosphate-
buffered saline/formaldehyde 4% and embedded in paraffin.
To quantify vein graft thickening, sequential cross sections
were made throughout the embedded vein grafts. For each
mouse, six equally spaced, representative sections per vessel
segment (n  8 per group) were used after being stained
with hematoxylin-phloxine-saffron (HPS).
Vein graft thickening was defined as the area between
the lumen and the adventitia and determined by subtract-
ing the luminal area from the total vessel wall area. No
distinction between intima and media was made, because
no morphologic border exists between the neointima and
media (like internal elastic lamina in arteries).13 Image
analysis software was used to quantify the vein graft thick-
ening (Leica Qwin, The Netherlands).
The composition of vein graft thickening was visualized
by HPS staining and immunohistochemistry (n  8 per
group). SMCs and macrophage-derived foam cells were
visualized with -SMC actin staining (anti-SM -actin,
dilution 1:750, Roche Applied Biosciences, Germany) and
AIA31240 antibody (1:1000, Accurate Chemical, United
States), respectively. MCP-1 and CCR2 expression in the
vein graft wall were detected by using an anti-mouse JE/
MCP-1 antibody (1:20, BD Biosciences, The Netherlands)
and an anti-CCR2 antibody (1:200, Abcam, United King-
dom).
SMCs and macrophage-derived foam cells immunopo-
sitive areas in the vein graft thickening were calculated as a
percentage of the total vein graft thickening area in cross
sections by means of image analysis software (Leica QWin).
CCR2 expression was quantified by counting the CCR2-
positive cells in the vessel wall per slide and divided by total
number of nuclei in these cross sections as determined by
hematoxylin staining. All histologic quantification was per-
formed in a single blinded fashion.
RNA isolation and real-time quantitative reverse
transcription polymerase chain reaction gene expres-
sion analysis. For gene expression analysis, vein grafts
were harvested and directly snap-frozen in liquid nitrogen
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per time point). RNA was isolated using RNeasy Fibrous
Tissue Mini Kit, and DNA contaminants were removed
by treatment with the RNase Free DNase set according
to the manufacturer’s protocols (Qiagen, The Nether-
lands). Complimentary DNA was synthesized by means
of Ready-To-Go Beads (Amersham Biosciences, The
Netherlands).
Quantitative analysis of mRNA levels was performed
using an ABI Prism 7700 sequence detection system (Ap-
plied Biosystems, United States) as described previously,14
and intron-spanning polymerase chain reaction (PCR)
primer sets were designed using Primer Express 1.5 soft-
ware (please see Appendix Table, online only, for sequences;
Applied Biosystems). Relative mRNA expression levels
(Ct) were calculated by subtracting the average cycle
threshold (Ct) per time point from the averaged Ct values
of the two housekeeping genes hypoxanthine phosphori-
bosyl transferase and cyclophilin (Ct  Ct target gene–
Ct average housekeeping genes). The Ct levels at each time
point were compared with the mRNA expression levels of
CCR2 and MCP-1 before surgery (Ct) and a mean fold
induction was calculated as 2–Ct.
Design, cloning, and validation of shRNA directed
against murine CCR2. Short hairpin CCR2 and lentiviral
vectors, as described by Bot et al, were used to intervene in
the vein graft model.9 Briefly, a pair of 64-nucleotide
oligonucleotides encoding a 19-nucleotide CCR2 shRNA
(5=-GATCCCC CTGTGTGAT TGACAAGCAC TTCAA-
GAGA GTGCTTGTC AATCAC ACAG TTTTTGGAAA-3=
and 5=-AGCTTTTCCAAAAA CTGTGTGATT GACAAG-
CAC TCTCTTGAA GTGCTTGT CAATCACACAG GGG-
3=) were designed. Nucleotides 867 to 885 (underlined)
represent the sequence targeting murine CCR2. The
pSUPER-H1.shCCR2 vector was constructed by anneal-
ing and cloning the 64-nucleotide oligonucleotides into
the pSUPER vector. Subsequently, lentiviral expression
vectors (Lenti-shCCR2 and control virus) were con-
structed, produced, and validated as previously described.9
Viral transduction of vein grafts in vivo. Viral trans-
duction of vein grafts was performed by application of
lentiviral constructs dissolved in Pluronic gel.15 During
surgery, 100 L Pluronic-127 gel (20% wt/vol; Sigma
Diagnostics, The Netherlands) dissolved in 0.9% saline
containing 108 IU Lenti-shCCR2 or a control lentiviral
vector expressing green fluorescent protein (Lenti-GFP)
and 10 g/mL diethylaminoethyl dextran (DEAE; Bio-
tech AB, Sweden) was applied to the adventitia. This for-
mula allowed the solution to form a gel after contact with
the vessel at 37°C, generating a translucent layer that
enveloped the grafted vessel segment, with the advantage
of prolonged release of approximately 2 days.16 The wo-
unds were closed after application of the gel.
Cell culture, SMC migration, and proliferation
assay. SMCs were obtained from thoracic aortas from
male C57BL/6 mice using the collagenase digestion me-
thod.17 Cells were cultured in a humidified atmosphere (5%
carbon dioxide) at 37°C in Dulbecco Modified Eagle Me-dium (DMEM, Gibco, Invitrogen, The Netherlands) con-
taining 10% fetal calf serum (Gibco), 2 mmol/L l-glutamine,
100 U/mL penicillin, and 100 g/mL streptomycin (all
from PAA, Germany).
SMCs were infected with Lenti-shCCR2 or the control
lentivirus at a multiplicity of infection of 15 in the presence
of 10 g/mL diethylaminoethyl-dextran (3 wells per
group). At 2 days after infection, SMCs were detached by a
short incubation with trypsin-ethylenediaminetetraacetic
acid (PAA) and seeded at a density of 5000 cells/well at an
80° angle, as described previously, to determine SMC
migration.18 After attachment of the cells to one side of the
well, murine MCP-1 (100 ng/mL, Immunosource, Bel-
gium) was added, plates were repositioned at a 20° angle,
and the cells were incubated overnight. The number of cells
that had migrated was scored manually and expressed as a
percentage of the control.
To determine the proliferative capacity of the SMCs
expressing Lenti-shCCR2, cells were seeded at a density of
2 104 cells/well (n 3). The cells were allowed to attach
and starved in DMEM containing 1% calf serum for 8 hours
to synchronize the cell cycle and then incubated for 24
hours with medium. After incubation, 0.5 Ci methyl-
[3H]-Thymidine (Amersham Biosciences, The Nether-
lands) was added per well and the cells were incubated
overnight at 37°C. Then the cells were lysated and
[3H]Thymidine incorporation was quantified as a measure
for DNA synthesis in a liquid scintillation analyzer (Packard
Tricarb 2900 TR, PerkinElmer,Germany) and expressed in
disintegrations per minute (dpm).
Statistical analysis. Results are expressed as mean 
standard error of the mean (SEM). Statistical significance
was calculated in SPSS 11.5 software (SPSS Inc, Chicago,
Ill). Differences between groups were determined and ex-
pression data (Ct) were statistically analyzed using t tests.
Values of P  .05 were considered statistically significant.
RESULTS
CCR2 and MCP-1 mRNA and protein expression
profiles in murine vein grafts in vivo. Real-time reverse-
transcription polymerase chain reaction (RT-PCR) was
used to analyze mRNA expression of CCR2 and MCP-1 in
vein grafts during the development of vein graft thickening
and accelerated atherosclerosis (n  3 per time point).
Expression of MCP-1 and its receptor CCR2 was minimal
in untreated caval veins. Already 6 hours after engraftment,
MCP-1 mRNA expression peaked with a 188  19-fold
increase, expressed in fold induction, compared with
mRNA expression level of MCP-1 in an untreated caval
vein (P  .001) and declined to a fold induction of 8.1 
2.0 after 28 days (P  .019; Fig 1, A). In contrast with
MCP-1, relative mRNA expression of CCR2 increased
more gradually from a 2.1  0.2-fold induction 6 hours
after surgery (P  .001 compared with the untreated caval
vein) to an 11.0 2.3-fold upregulation after 28 days (P
.009; Fig 1, B).
The in vivo presence of MCP-1 and CCR2 protein in
murine vein grafts in time was demonstrated by immuno-
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previous findings, MCP-1 was mainly expressed by endo-
thelial cells and in the adhering leukocytes in the first days
after engraftment. At 1 and 2 weeks after surgery, MCP-1
was mostly detectable in the thickened vessel wall, colocal-
izing with AIA31240-positive monocytes/macrophages as
assessed with immunohistochemistry on serial sections and
evaluating MCP-1 expression in relation to cell morphol-
ogy. This suggests that infiltrating macrophages express
MCP-1.8 Consistent with the mRNA expression of
MCP-1, after an initial increase, the expression of MCP-1
protein in the vessel wall decreased in time and almost
disappeared after 4 weeks (Fig 2, A).
The expression pattern of CCR2 protein was comparable
with MCP-1. CCR2 was present in the adhering leukocytes
directly after surgery, and expression increased throughout
the whole vessel wall, colocalizing with infiltrating macro-
phages and SMCs, in the consecutive weeks (also assessed
with immunohistochemistry on serial sections in relation to
cell morphology; Fig 2, B). Contrary to the MCP-1 expres-
sion, CCR2 protein expression did not decline and was still
detectable 4 weeks after bypass placement, which corresponds
with the CCR2 mRNA expression data.
Lentiviral shCCR2 reduces vascular smooth muscle
cell migration and proliferation. The functional effects
of shCCR2 on SMC migration and proliferation in vitro
were studied in cultured SMCs obtained from murine
thoracic aortas. SMCs were transduced with either Lenti-
empty as a control vector or Lenti-shCCR2 (3 wells with
5000 cells each per group). One day after stimulation with
murine MCP-1, migration of SMCs infected with control
virus was increased to 130%  9% compared with the
nonstimulated control group. In contrast, adding MCP-1
did not stimulate migration of SMC after being transduced
with Lenti-shCCR2 (93%  7% migration compared with
the control, P  .001; Fig 3, A).
Next, [3H]thymidine incorporation was used to assess
SMC proliferation. After transducing SMCs with Lenti-
empty or Lenti-shCCR2 and synchronizing the cell cycle,
methyl-[3H]-Thymidine was added (n  3). When trans-
duced with Lenti-shCCR2, DNA synthesis was signifi-
cantly decreased compared with both nontransduced
SMCs and SMCs infected with the empty vector (control,
85  104  1 104 dpm; empty, 85  104  0.8  104
dpm; shCCR2, 81 104  0.9  104 dpm; P  .031 and
P  .015, respectively; Fig 3, B).
Local knock-down of CCR2 expression inhibits
vein graft thickening in vivo. Before the effect of Lenti-
shCCR2 on vein graft thickening could be studied, the
transduction efficiency of lentiviral vectors to murine veins
was determined (n  4 per group; Fig 4, E).
To study the effect of shCCR2 on vein graft thickening
in hypercholesterolemic mice, caval veins from donor mice
were placed in male APOE*3-Leiden mice. During sur-
gery, vein grafts were transduced by application of lentivi-
rus encoding for either Lenti-shCCR2 or Lenti-GFP as a
control dissolved in Pluronic gel (n  8 per group).At the start of the experiment, mean serum cholesterol
levels were 11.1  3.0 mmol/L in the shCCR2-treated
group and 7.6  1.0 mmol/L in the control mice (differ-
ence not significant, P .13). Also during the experiment,
mean cholesterol levels and body weights of all mice in both
groups did not change significantly (data not shown).
Four weeks after bypass placement, histomorphometric
analysis was performed on the vein grafts. A 38% reduction
of vein graft thickening area was found in the Lenti-
shCCR2–treated animals (0.26  0.03 mm2) compared
with the control group (0.42 0.05mm2; P .007; Fig 4,
A). The total vessel wall area in the shCCR2-treated group
was less expanded (0.70  0.06 mm2) compared with the
control group (0.93  0.05 mm2; P  .006). However,
luminal area did not diverge between the groups, indicating
Fig 1. Relative CC-chemokine receptor (CCR2) and monocyte
chemoattractant protein-1 (MCP-1) cytokine expression profiles in
vivo. A, Relative messenger RNA (mRNA) expression levels of
MCP-1 and (B) CCR2 in the vein graft at several time points after
surgery as determined by real-time reverse transcription polymer-
ase chain reaction (n  3 per time point). Relative mRNA expres-
sion is expressed as fold induction  standard error of the mean,
whereas the expression of MCP-1 or CCR2 mRNA in the normal-
ized untreated veins is defined as 1.an inhibition of outward remodeling after shCCR2 treat-
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tor 2 (CCR2) in vein grafts in time. Representative cross-sections of vein grafts harvested at 6 hours, and 1, 14, and 28
days after surgery. A, MCP-1 and (B) CCR2 expression in the vessel wall were visualized with an anti-mouse
JE/MCP-1 and an anti-CCR2 antibody, respectively. MCP-1 and CCR2 expression could be detected in the adhering
monocytes and in the infiltrating cells, depending of the stage of the developing vein graft thickening. Symbols indicate
the several cell types (*for adhering leukocytes, # for macrophages, and arrows for smooth muscle cells). The inserts
represent enlargements of the specific cell types. All images are at original magnification 200 to 400. Scale bars
represent 10 or 20 M, as indicated.
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mm2; P  .26; Fig 4, B and C).
The effect of shCCR2 treatment on cellular compo-
sition of the vein graft lesions was studied by immuno-
histochemical analysis for the presence of SMCs and
lipid-loaded macrophages (Table). Four weeks after sur-
gery, no significant differences in relative contribution to
Fig 3. Short hairpinCC-chemokine receptor 2 (shCCR2) attenuates
smooth muscle cell (SMC) migration and proliferation. A, Adding
monocyte chemoattractant protein-1 (MCP-1) to cultured SMCs did
not stimulate migration of SMCs that were transduced with lentiviral
shCCR2; however, migration of SMCs transduced with control vec-
tor was increased by adding MCP-1, as detected with a SMC migra-
tion assay. Migration of cells was scored manually in one microscopic
view and is expressed as a percentage of the control. B, SMC prolif-
eration was inhibited in SMCs expressing lentiviral shCCR2 com-
pared with SMCs transduced with Lenti-empty or the control group.
Proliferation capacity of SMCs was determined by means of quantify-
ing [3H]thymidine incorporation as a measure for DNA synthesis.
Incorporation of [3H]thymidinewasmeasured in a liquid scintillation
analyzer and is expressed in mean disintegrations/minute (counts/
minute) with the standard error (error bars).the cellular composition were seen for thickened vesselwall area positive for SM-actin (expressed as positive
stained area as a percentage of the total area), for
shCCR2 (11%  6%), compared with the control group
(10% 3%; P .45), or for the lipid-loaded macrophage
content of the shCCR2-treated mice (11%  2%) vs
control (9%  2%; P  0.22).
Although local application of shCCR2 resulted in a
significant inhibition of vein graft thickening and thus
reduced the absolute number of CCR2-positive cells in the
vein graft lesions, this treatment did not alter the relative
abundance of CCR2 positively stained cells in the vessel
wall in both groups after 28 days (control, 44%  5%;
shCCR2, 50%  8%; P  .52; Table).
DISCUSSION
Long-term patency of vein grafts is mainly compro-
mised by vein graft thickening due to intimal hyperplasia
and accelerated atherosclerosis. Inflammatory processes
initiated by damage of the vascular wall after surgery and
an altered shear stress lead to recruitment, adhesion, and
influx of monocytes, followed by SMC migration and
proliferation.6,19 MCP-1 and its receptor, CCR2, are
important mediators in monocyte recruitment and mac-
rophage accumulation, thereby playing a key role in the
process of vascular inflammation and the initiation of
atherosclerosis.20-22 We previously demonstrated the in-
volvement of the MCP-1/CCR2 pathway in the devel-
opment of vein graft disease.8,23 This study demon-
strated that silencing of CCR2 in vascular cells by means
of locally expressed shRNA reduces vein graft thickening
in vivo, indicating new therapeutic interventions based
on this approach.
The presence of MCP-1/CCR2 mRNA and protein
during the development of vein graft thickening in vivo
was demonstrated by real-time RT-PCR and immuno-
histochemistry, respectively. MCP-1 mRNA and protein
expression both peaked early and diminished in time.
CCR2 mRNA expression could be detected directly after
surgery and increased gradually during vein graft devel-
opment. It is mainly transcriptionally regulated,24 mak-
ing it an attractive candidate for silencing by small inter-
fering (siRNA).
Next, targeted gene silencing by means of a lentivi-
ral vector expressing shRNA, developed against CCR2
(shCCR2), was used to interfere in the MCP-1/CCR2
pathway.We show an inhibitory effect of Lenti-shCCR2 on
MCP-1–induced SMC migration and proliferation in vitro
that underscores the importance of the MCP-1/CCR2
pathway in SMCs migration and proliferation next to its
monocyte chemoattractant characteristics8 as well as on
vein graft thickening in vivo.
RNA interference is a promising strategy to analyze gene
function and to interfere in different disease models and may
have a strong therapeutic potential. Because of the superior
stability of siRNAs and an extended choice in target genes, the
use of siRNAs is preferable to, for example, antisense oligode-
oxynucleotides.25 Application of RNA in vivo requires effi-
cient delivery of siRNA to the target tissue and long-termgene
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apolipoprotein E3 (APOE*3)-Leiden mice. A, Vein graft thickening, (B) total vessel wall, and (C) luminal area of
APOE*3-Leiden mice (n  8 per group) 4 weeks after vein graft surgery and local infection of the vein graft with
lentiviral shCCR2 or a control lentivirus. Areas were quantified by using six sequential sections per segment and are
expressed in mean mm2 ( standard error of the mean, error bars). Treatment with shCCR2 resulted in a significant
reduction of (A) vein graft thickening and (B) total vessel wall area (P  .007). C, Luminal area was not affected by
shCCR2 treatment. D, Photomicrographs of hematoxylin-phloxine-saffron (HPS) staining of (left) control and
(right) vein grafts. The black line indicates vein graft thickening. Original magnification200.E, Fluorescent and light
microscopy images are shown of cryo-cross sections of vein grafts after engraftment and infection with a lentiviral vector
expressing green fluorescent protein (Lenti-GFP). Explanted vein grafts of donor mice were incubated in a solution of
Pluronic gel dissolved in 0.9% saline containing 108 IU Lenti-GFP or no virus to assess auto-fluorescence and
10 g/mL diethylaminoethyl-dextran for 30 minutes at room temperature. Directly after implantation of these vein
grafts in male APOE*3-Leiden mice, this solution was applied to the adventitia. In an environment of 37°C, it forms
a translucent solid layer and envelops the graft. Three days after surgery, veins were harvested and cryo-cross sections
of the veins were made. GFP is expressed throughout the whole vessel wall after infection, whereas only some
auto-fluorescence is seen in the untreated veins. The images were taken with a Leica DM-RE microscope (original
magnification 200; scale bars represent 10 M).
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efficiently and warrant long-term shRNA expression as indi-
cated in this study.27,28 Moreover, third-generation lenti-
viruses, as used in this study, are self-inactivating and
nonintegrating vectors that provide safe and stable trans-
gene expression.29 When transduction is applied directly
on the target tissue, the occurrence of systemic side
effects is even less likely. In the present study, gene-
specific silencing locally in the vascular target tissue was
obtained by efficient and prolonged expression of a
shRNA construct after lentiviral infection of the vein
segments, resulting in inhibition of vein graft thickening
in a murine model for vein graft disease.
The role of CC-chemokines in vein graft thickening
was studied previously. Ali et al30 reported that systemic
adenoviral-delivered broad-spectrum CC-chemokine in-
hibitor reduced accelerated atherosclerosis in vein grafts,
underscoring the role of CC-chemokines in the develop-
ment of vein graft disease. No conclusion about the role of
CCR2 in particular could be drawn, however, due to the
broad-spectrum character of the CC-chemokine inhibitor
used in this study. Alternatively, the use of siRNA, shRNA, or
specific receptor antagonists makes it possible to investigate a
specificCC-chemokine or pathway.Recently, Tatewaki et al23
described that local ex vivo adenoviral mediated gene transfer
of CCR2 antagonist, 7ND-MCP-1, limited vein graft thick-
ening in dogs. This is similar to our previous findings in mice,
where we used systemic overexpression of a plasmid vector
encoding the same antagonist (7ND-MCP-1) by means of
electroporation-mediated gene transfer into skeletal muscle,
and emphasizes the important role of MCP-1 and CCR2 in
the pathogenesis of vein graft disease.8
The adenoviruses in the current generation are not very
suitable for an eventual clinical application considering the
relatively low transduction efficiency for vascular tissue, their
preexisting immunity, and the risk of undesired effects such as
liver toxicity. Although much progress is made in the genera-
tion of improved adenoviral vectors for vascular tissue infec-
tion, reduced immunogenicity, and evenwith less pre-existing
immunity in the human population, these newer generations
of adenoviruses still are not fully applicable to the human
Table. Quantitative analysis of effect of short hairpin
CC-chemokine receptor 2 treatmenta
Variable Control shCCR2
Smooth muscle cellsb 10.4  2.7 11.1  5.7
Macrophagesb 9.0  1.5 10.8  1.8
CCR2c 44.3  5.4 50.3  7.6
CCR2, CC-chemokine receptor 2; shCCR2, short hairpin CC-chemokine
receptor 2.
aResults were determined by immunohistochemistry and values are ex-
pressed as mean  standard error of the mean. None of the differences
between the control and shCCR2 groups are significant.
bExpressed as percentage of total vein graft thickening.
cPositively stained cells are expressed as a percentage of total number of cells.situation.31In our study, shCCR2 had an inhibitory effect on SMC
proliferation and migration as well as on monocyte infiltra-
tion.Thiswas reflected in an equally relative presence of SMCs
andmonocytes in the plaques of the vein grafts locally treated
with shCCR2 and in the control groups, although these
plaques show significant differences in size. Relative abun-
dance of CCR2 positively stained cells in the vessel wall was
not significantly different in both groups after shCCR2 treat-
ment. Together with the reduction of the absolute number of
CCR2-positive cells in the vein graft lesions, however, the
total number of vascular cells was also reduced in this group
due to inhibition of vein graft thickening. Taken together, this
indicates that shCCR2 not only hampered monocyte chemo-
taxis but also had a direct inhibitory effect on SMCsmigration
and proliferation in vitro as well as in vivo.
CONCLUSIONS
In this study we have demonstrated that lentiviral de-
livery of shCCR2 blocks migration and proliferation of
SMCs and inhibits vein graft thickening in vivo when
delivered directly and locally to the vessel wall, stressing the
significant involvement of the MCP-1/CCR2 pathway in
the process of vein graft disease in hypercholesterolemic
APOE*3-Leidenmice. Therefore, this local overexpression
of shRNA by, for instance, lentiviral vector delivery as
shown in this study, is a very promising therapeutic tool to
improve vein graft patency.
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